INCY – PDUFA Trade Note

Incyte Pharmaceuticals is awaiting FDA approval of its lead compound Ruxolitinib (INCB18424) for the treatment of Myelofibrosis (MF) with an expected decision date on December 3, 2011.  Our analysis suggests.

Trade Strategy: Approaching Catalysts

Its end of year 2011 and there are a large quantity of trading opportunities approaching. On the docket: $ALIM – PDUFA (NOV 12, 2011) $SPPI – PDUFA (NOV 20, 2011).

BMTI – Trade Note

HIGHLY SPECULATIVE TRADE Overview In May 2011 BioMimetic Therapeutics (BMTI) received a positive recommendation from the FDA Advisory Committee for their Augment Bone Graft technology. Despite this, the FDA was.

DEPO – Trading BREEZE-3 Results

Overview In the next several weeks Depomed (DEPO) is expected to announce top-line results from it’s large Phase 3 clinical trial for Serada, an investigational non-hormonal treatment for post-menopausal hot.

Browsing 4 / 224 articles